EN
抗体药类似物
Research Grade Ulocuplumab
All
  • CatalogTD-HX206016
  • ClonalitymAb
  • Application Research Grade Biosimilar
  • SynonymsBMS-936564,MDX-1338,MDX1338,CAS:1375830-34-4
  • 规格
    1mg
  • 价格
    ¥询价
定制服务咨询

Research Grade Ulocuplumab


Catalog No. TD-HX206016
Description Ulocuplumab (BMS-936564) is a first-in-class fully human IgG4 monoclonal anti-CXCR4 antibody that inhibits the binding of CXCR4 to CXCL12. The CXCR4/CXCL12 (SDF-1) axis has been known for many years as a critical regulator of tumor proliferation, cell, as well as migration into and out of the bone marrow.
Species reactivity Human
Applications Research Grade Biosimilar
Host species Human
Isotype IgG4-kappa
Expression system Mammalian Cells
Clonality TD-Monoclonal
Target Stromal cell-derived factor 1 receptor, LCR1, HM89, LPS-associated protein 3, LAP-3, CXC-R4, CXCR-4, SDF-1 receptor, CD184, NPYRL, LESTR, Fusin, FB22, C-X-C chemokine receptor type 4, CXCR4, Lipopolysaccharide-associated protein 3, Leukocyte-derived seven transmembrane domain receptor
Endotoxin level Please contact the lab for this information.
Purity >95% purity as determined by SDS-PAGE.
Purification Protein A/G, purified from cell culture supernatant.
Accession P61073
Form Liquid
Storage buffer 0.01M PBS,pH7.4.
Stability and Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names BMS-936564,MDX-1338,MDX1338,CAS:1375830-34-4
Background Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models.
Note For research use only. Not for use in clinical or therapeutic applications.